U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H22N2O
Molecular Weight 294.3908
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BGC-20-761

SMILES

COC1=CC2=C(NC(=C2CCN(C)C)C3=CC=CC=C3)C=C1

InChI

InChIKey=VSGPGYWZVPDDSK-UHFFFAOYSA-N
InChI=1S/C19H22N2O/c1-21(2)12-11-16-17-13-15(22-3)9-10-18(17)20-19(16)14-7-5-4-6-8-14/h4-10,13,20H,11-12H2,1-3H3

HIDE SMILES / InChI
Molecular Formula C19H22N2O
Molecular Weight 294.3908
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16298400

BGC 20761 is an orally active, tryptamine analogue that is being developed by BTG as a procognitive antipsychotic for the treatment of schizophrenia. Preclinical development is underway in the US. This serotonin6 and serotonin2A receptor antagonist has nootropic properties with a balance of serotonergic and dopaminergic antagonist activity; BGC 20761 has moderate to low affinity for dopamine2, serotonin2C, histamine1, muscarinic M1-5, and α1 adrenergic receptors, indicating a potentially low propensity to cause serious adverse events.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
 47.0 nM [Ki]
Antagonist
2849
 470.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
BGC20-761, a novel tryptamine analog, enhances memory consolidation and reverses scopolamine-induced memory deficit in social and visuospatial memory tasks through a 5-HT6 receptor-mediated mechanism.
2006-03
Patents

Patents

US20080171779 A1
1

Sample Use Guides

In Vivo Use Guide
BGC20-761 (10 mg/ml saline-based solution), was administered (i.p.) to male 8-week-old LongeEvans rats and 4-week-old SpragueeDawley rats at doses of 2.5 mg/kg, 5 mg/kg and 10 mg/kg. BGC20-761 (10 mg/kg i.p.) alone had no effect on social recognition in young rats, however, at doses of 5 mg/kg and 10 mg/kg i.p, BGC20-761 dose-dependently reversed a deficit of social recognition induced by scopolamine (0.4 mg/kg i.p.), an anticholinergic drug that impairs memory.
Route of Administration: Intraperitoneal
In Vitro Use Guide
The affinity of BGC20-761 for rat 5-HT6 receptors stably expressed in HeLa cells was determined by competition radioligand binding assay using [3H]-5-HT as radioligand. BGC20-761 shows potent binding to 5-HT6 receptors with Ki=46 nM
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:40:42 GMT 2025
Edited
by admin
on Mon Mar 31 22:40:42 GMT 2025
Record UNII
6G5F6ESV5I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BGC-20-761
Common Name English
1H-INDOLE-3-ETHANAMINE, 5-METHOXY-N,N-DIMETHYL-2-PHENYL-
Preferred Name English
INDOLE, 3-(2-(DIMETHYLAMINO)ETHYL)-5-METHOXY-2-PHENYL-
Systematic Name English
N,N-DIMETHYL-2-(5-METHOXY-2-PHENYLINDOL-3-YL)ETHYLAMINE
Systematic Name English
Code System Code Type Description
PUBCHEM
6918515
Created by admin on Mon Mar 31 22:40:42 GMT 2025 , Edited by admin on Mon Mar 31 22:40:42 GMT 2025
PRIMARY
CAS
17375-63-2
Created by admin on Mon Mar 31 22:40:42 GMT 2025 , Edited by admin on Mon Mar 31 22:40:42 GMT 2025
PRIMARY
FDA UNII
6G5F6ESV5I
Created by admin on Mon Mar 31 22:40:42 GMT 2025 , Edited by admin on Mon Mar 31 22:40:42 GMT 2025
PRIMARY
Related Record Type Details
Structure of BGC-20-761
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966